There is no cap on ChondroFiller injections

For some patients, one ChondroFiller injection is all that is needed. When a focal cartilage defect is contained and addressed early, a single ultrasound-guided treatment can provide the scaffold the joint requires, and no further injections are planned.

For others — particularly those with an ongoing mechanical or degenerative environment in the joint — the question of repeat treatment is equally straightforward: there is no upper limit. Patients can receive ChondroFiller injections across their lifetime, without a predetermined ceiling on how many courses are appropriate.

The structure that governs repeat treatment is the Lifetime Preservation Programme (LLP), a clinic-led joint preservation protocol that schedules a ChondroFiller top-up injection every two years, indefinitely, for patients who enrol in it. The rationale is biological rather than administrative: articular cartilage has no meaningful capacity for spontaneous repair, so the joint environment that permitted the original defect to develop does not simply resolve after a single treatment. Maintenance is built into the programme by design.

The three pillars of the Lifetime Preservation Programme

Three distinct components make up the LLP, and each serves a different function in the joint.

Pillar one: yearly collagen peptide supplementation. Between injections, patients take an annual course of collagen peptides to support the joint environment — providing the nutritional substrate the avascular cartilage layer cannot draw from a blood supply. This does not replace the scaffold, but it sustains the biological conditions in which the scaffold is expected to perform.

Pillar two: annual MRI monitoring. Each year, the joint is reimaged to assess scaffold integrity and the surrounding cartilage. This is not passive surveillance. If the MRI shows that degradation is progressing faster than anticipated — before the standard two-year mark — the findings can bring a top-up injection forward. The scan actively governs the schedule rather than simply confirming it.

Pillar three: biennial ChondroFiller top-up injection. Every two years, a further ultrasound-guided ChondroFiller injection replenishes the collagen scaffold before it is fully resorbed. Published data suggest the scaffold undergoes complete biological turnover and replacement by host tissue over approximately two years, which is why the interval is set where it is — though the London Cartilage Clinic notes this schedule is protocol-specified and may be adjusted in response to imaging findings.

Taken together, the three pillars function as a single adaptive protocol rather than three parallel routines. The stated aim — lifetime joint preservation and a reduced probability of ever reaching total knee or hip replacement — depends on all three working in sequence, with the MRI acting as the mechanism by which the programme responds to the individual rather than following a rigid timetable.

Why cartilage needs periodic top-ups rather than a one-off fix

The answer lies in two properties that distinguish articular cartilage from almost every other connective tissue in the body.

Unlike bone or muscle, articular cartilage contains no blood vessels. Nutrients reach the chondrocytes — the cells responsible for maintaining the matrix — by diffusion through synovial fluid alone, a process too slow and spatially limited to deliver meaningful repair cells to a damaged site. Cell density within the tissue is also extremely low, leaving no resident population capable of mounting the kind of regenerative response that a bone fracture, for example, would automatically trigger. Once damage passes the threshold where diffusion-based maintenance can compensate, it does not reverse without external intervention.

The second complication is environmental persistence. The conditions that produced the original defect — abnormal load distribution, low-grade synovial inflammation, wear propagating from adjacent cartilage — do not resolve when the collagen scaffold is placed. They continue to act on the joint and, over time, degrade the matrix from the outside in. This is precisely why replenishment before complete resorption matters: if the scaffold is fully eroded before a top-up is delivered, the defect site is left structurally unprotected and exposed to the same erosive forces that caused the original damage.

The two-year injection interval maps to the known degradation timeline of the collagen scaffold, making it biologically coherent. It should be noted, however, that this interval is protocol-specified — the product of clinical experience and scaffold pharmacokinetics — rather than the outcome of a randomised trial directly comparing different top-up frequencies.

What annual MRI monitoring actually involves

The annual MRI is included within the LLP's maintenance charge — patients do not arrange or fund it separately, and it does not sit outside the programme as an additional cost to manage.

Structurally, the scan assesses the scaffold using MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue), a validated imaging framework that evaluates defect fill, tissue integration, and the signal characteristics of the maturing graft site. MOCART scores documented in London Cartilage Clinic cohort data have ranged between 70 and 87, giving the clinician an objective benchmark against which year-on-year structural changes can be tracked and interpreted.

The scan covers more than the graft site alone. Adjacent cartilage surfaces and the subchondral bone plate beneath the defect are also reviewed, because deterioration in those neighbouring structures can place additional mechanical load on the scaffold and accelerate matrix erosion — even when the graft itself appears intact on imaging.

Each annual scan doubles as a clinical review appointment. If a patient's activity level, body weight, or symptom profile has shifted since the previous visit, the care plan can be adjusted in response. Where imaging reveals structural change progressing more quickly than the standard schedule anticipates, the clinician has objective data to support an earlier top-up rather than waiting on symptoms to make the case.

Where the LLP sits in the treatment ladder and what it costs

Pricing for ChondroFiller treatment at London Cartilage Clinic follows a straightforward ladder for one-off options. A standalone ChondroFiller injection starts at £3,000 for a single box — a route that suits patients with a contained focal defect who do not require ongoing programme enrolment. For patients with more advanced disease (Kellgren–Lawrence Grade III or IV osteoarthritis), a combined ChondroFiller and Arthrosamid dual injection is available at £6,000. The two products address different problems: ChondroFiller acts as a regenerative collagen scaffold, recruiting the patient's own progenitor cells to rebuild the cartilage matrix, while Arthrosamid is a non-regenerative polyacrylamide hydrogel that cushions the joint. They are not interchangeable, and should not be confused with one another. Above both sits Tri-Active Therapy with autologous mesenchymal stem cells, priced at £11,000.

The LLP occupies a different tier altogether. Rather than a single upfront charge, it is structured as an annual maintenance fee — covering collagen peptide supplementation and MRI monitoring — plus a separate bi-annual fee for each top-up injection. Neither figure is publicly listed; patients receive an individualised quote at assessment, reflecting their joint status and programme stage.

The programme suits patients seeking proactive, indefinite joint preservation rather than a single episode of care. It is not the appropriate choice for every patient, and suitability is determined at clinical assessment rather than by self-selection.

Whether the LLP is suitable for you and how to find out

Deciding whether the LLP is the right structure for you depends primarily on the nature of your cartilage damage. The programme is most relevant to patients with a confirmed focal defect who want proactive, long-term protection rather than waiting for symptoms to resurface after an initial injection. Patients who have already received a single ChondroFiller injection can enrol retrospectively — the LLP does not require starting from scratch, and the first annual MRI simply establishes the new baseline.

Diffuse or end-stage osteoarthritis — where much of the articular surface is affected rather than a discrete lesion — is a different clinical conversation. The LLP is designed for joint preservation, not for joints where the preservation window has already closed.

For those who are suitable, the top-up injections that anchor the programme are ultrasound-guided outpatient procedures. They do not involve surgery, general anaesthesia, or a hospital admission — a practical consideration for patients managing a working life around their care.

An initial assessment with Professor Paul Lee at the London Cartilage Clinic on Harley Street determines whether the LLP is appropriate, establishes the diagnostic baseline, and clarifies what the programme would involve for your specific joint and defect profile. Appointments and further information are available at londoncartilage.com.